Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes
Authors:
Open Access
- 5 August 2020
- journal article
- research article
- Published by Springer Nature in Diabetology & Metabolic Syndrome
- Vol. 12 (1) , 1-7
Abstract
Background: The chronic complications of Type 2 Diabetes (T2D) such as macrovascular disease is amplified with the increase in the number of metabolic syndrome (MetS) risk factors. This research aims to study the relationship of MetS, diagnosed by the International Diabetes Federation (IDF) or revised National Cholesterol Education Programs Adult Treatment Panel III (NCEP ATP III) criteria, with glycemic control, fasting blood glucose (FBG), glycated hemoglobin (HbA1c), C-peptide, and insulin resistance in T2D patients. Methods: The study is a cross-sectional observational study which, involved 485 T2D patients who are receiving treatment at the University Kebangsaan Malaysia Medical Center (UKMMC), Kuala Lumpur, Malaysia. The MetS among the T2D patients was diagnosed based on IDF and revised NCEP ATP III criteria. C-peptide and HbA1c levels were determined by an automated quantitative immunoassay analyzer and high-performance liquid chromatography, respectively. The MetS factors; FBG, triglyceride, and high-density lipoprotein cholesterol were measured by spectrophotometer. Results: Application of the IDF and revised NCEP ATP III criteria respectively resulted in 73% and 85% of the T2D subjects being diagnosed with MetS. The concordance of these criteria in diagnosing MetS among T2D patients was low (κ = 0.33, P < 0.001). Both IDF and revised NCEP ATP III criteria indicated that T2D patients with 5 MetS factors had higher insulin resistance (P = 2.1 × 10−13; 1.4 × 10−11), C-peptide (P = 1.21 × 10−13; 4.1 × 10−11), FBG (P = 0.01; 0.021), and HbA1c (P = 0.039; 0.018) than those T2D patients without MetS, respectively. Conclusion: Although there is a low concordance between IDF and revised NCEP ATP III criteria in the diagnosis of MetS among T2D patients, both criteria showed that T2D patients with 5 MetS factors had higher insulin resistance, C-peptide, FBG, and HbA1c.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Prevalence of Metabolic Syndrome in Type 2 Diabetes Mellitus Using NCEP-ATPIII, IDF and WHO Definition and Its Agreement in Gwalior Chambal Region of Central IndiaGlobal Journal of Health Science, 2013
- Metabolic syndrome in type 2 diabetes: comparative prevalence according to two sets of diagnostic criteria in sub-Saharan AfricansDiabetology & Metabolic Syndrome, 2012
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Metabolic Syndrome PandemicArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Comparison of the Prevalence of the Metabolic Syndrome by WHO, AHA/NHLBI, and IDF Definitions in a German Population with Type 2 Diabetes: The Diabetes in Germany (DIG) StudyHormone and Metabolic Research, 2007
- Metabolic Syndrome and Risk of Cardiovascular Disease: A Meta-AnalysisThe American Journal of Medicine, 2006
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Current issues and forthcoming eventsJournal of Advanced Nursing, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Cellular mechanisms of insulin resistanceJournal of Clinical Investigation, 2000